Ginkgo Bioworks Holdings Inc (DNA)
0.7609
-0.16
(-17.29%)
USD |
NYSE |
May 10, 16:00
0.7598
0.00 (0.00%)
After-Hours: 20:00
Ginkgo Bioworks Holdings Enterprise Value: 732.05M for May 10, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 10, 2024 | 732.05M |
| May 09, 2024 | 1.083B |
| May 08, 2024 | 1.024B |
| May 07, 2024 | 1.113B |
| May 06, 2024 | 1.233B |
| May 03, 2024 | 1.160B |
| May 02, 2024 | 952.77M |
| May 01, 2024 | 910.91M |
| April 30, 2024 | 1.019B |
| April 29, 2024 | 1.236B |
| April 26, 2024 | 950.56M |
| April 25, 2024 | 769.05M |
| April 24, 2024 | 919.06M |
| April 23, 2024 | 973.47M |
| April 22, 2024 | 912.46M |
| April 19, 2024 | 961.14M |
| April 18, 2024 | 1.093B |
| April 17, 2024 | 975.90M |
| April 16, 2024 | 1.068B |
| April 15, 2024 | 1.148B |
| April 12, 2024 | 1.280B |
| April 11, 2024 | 1.368B |
| April 10, 2024 | 1.522B |
| April 09, 2024 | 1.553B |
| April 08, 2024 | 1.445B |
| Date | Value |
|---|---|
| April 05, 2024 | 1.381B |
| April 04, 2024 | 1.359B |
| April 03, 2024 | 1.402B |
| April 02, 2024 | 1.316B |
| April 01, 2024 | 1.467B |
| March 28, 2024 | 1.553B |
| March 27, 2024 | 1.424B |
| March 26, 2024 | 1.359B |
| March 25, 2024 | 1.402B |
| March 22, 2024 | 1.359B |
| March 21, 2024 | 1.510B |
| March 20, 2024 | 1.531B |
| March 19, 2024 | 1.402B |
| March 18, 2024 | 1.402B |
| March 15, 2024 | 1.381B |
| March 14, 2024 | 1.337B |
| March 13, 2024 | 1.574B |
| March 12, 2024 | 1.574B |
| March 11, 2024 | 1.682B |
| March 08, 2024 | 1.682B |
| March 07, 2024 | 1.639B |
| March 06, 2024 | 1.682B |
| March 05, 2024 | 1.531B |
| March 04, 2024 | 1.768B |
| March 01, 2024 | 1.833B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
732.05M
Minimum
May 10 2024
23.28B
Maximum
Nov 08 2021
4.565B
Average
2.769B
Median
May 09 2022
Enterprise Value Benchmarks
| Agenus Inc | 192.11M |
| Teladoc Health Inc | 2.468B |
| Sarepta Therapeutics Inc | 12.31B |
| Ultragenyx Pharmaceutical Inc | 2.988B |
| Apellis Pharmaceuticals Inc | 4.863B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -211.69M |
| Revenue (Quarterly) | 34.76M |
| Total Expenses (Quarterly) | 212.87M |
| EPS Diluted (Quarterly) | -0.11 |
| Gross Profit Margin (Quarterly) | 80.98% |
| Profit Margin (Quarterly) | -609.1% |
| Earnings Yield | -61.77% |
| Normalized Earnings Yield | -49.28 |